Results from extensively drug-resistant TB treatment study released
Analysts determined that the Phase 2b trial demonstrated a background regimen combined with delamanid may treat difficult-to-treat, complex XDR-TB patients. After the trial subjects received this regimen for two months, they proved to be non-infectious when compared to other subjects who received only a placebo combined with a background regimen.
“XDR-TB is one of the most deadly and difficult forms of TB to treat,” Andra Cirule, one of the lead study investigators and a tuberculosis specialist at Riga East University Hospital in Latvia, said. “More new medicines are urgently needed to prevent XDR-TB from becoming a death sentence and if confirmed, this analysis shows that delamanid may be an effective option to improve the current standard of care.”
In 2014, exactly 100 countries (the US included) confirmed a minimum of one XDR-TBi case, which has proven resistant to first-line drugs rifampicin and isoniazid in addition to other treatments, making treatments for this illness crucial to worldwide health.
“The study’s important findings reaffirm Otsuka’s commitment to continued research into this major global health threat,” Masuhiro Yoshitake, executive operating officer of Otsuka and TB Global Project leader, said. “For over 40 years, Otsuka has made it a priority to identify new treatment options for even the most challenging TB cases, and we look forward to potential progress against this deadly strain.”